Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 232

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Synthetic Lethality — A New Direction in Cancer-Drug Development

Iglehart, J. Dirk, Silver, Daniel P.·2009·New England Journal of Medicine

Abstract

In this issue of the Journal, Fong et al. report the results of a phase 1 trial of a new cancer therapy involving 60 patients (ClinicalTrials.gov number, NCT00516373).1 Readers may be surprised by the editors' decision to publish a small early-stage trial, but this trial not only reports important results — it also points to a new direction in the development of anticancer drugs. Modern cancer-drug discovery focuses on finding new therapies with few side effects by leveraging advances in the understanding of cancer biology, but barriers to success are substantial. The story behind the report by Fong et al. . . .

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1056/nejme0903044

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 5 references

Cited by

See all 232

Metadata

Authors
Iglehart, J. D., & Silver, D. P.
Venue
New England Journal of Medicine
Published
2009-07-09
Volume
361
Issue
2
Pages
189-191
ISSN
  • 0028-4793 (ISSN-L)
  • 1533-4406
OpenAlex
W1966182052
Cited by
232
References
5
FWCI
10.29
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Synthetic Lethality — A New Direction in Cancer-Drug Development. https://app.cochat.ai/papers/10.1056/nejme0903044
The paper
Iglehart, J. D., & Silver, D. P. (2009). Synthetic Lethality — A New Direction in Cancer-Drug Development. New England Journal of Medicine. https://doi.org/10.1056/nejme0903044

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.